parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in pituitary stem cells	0.75
chemistry Open Targets	reachable by antibody	0.36
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 10934

ADGRA3 in astrocytes, braak+0.00 (p 1.000) → +0.02 (p 0.962)receipt 10940
ADGRA3 in dopamine neurons, braak+0.34 (p 0.373) → -0.47 (p 0.204)receipt 10941

receipt 10941: ADGRA3 in dopamine neurons, braak

power: full sample -0.02 (p 0.935, n 18), 95% CI -0.48 to +0.45. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.03 (p 0.908, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.01 (p 0.976, n 18). could be the mix.
skeptic: leave-one-out range -0.18 to +0.09, sign flips 7; without severely affected donors -0.02 (p 0.935, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ADGRA3 in dopamine neurons.

case closed: nothing better to follow up.

receipt 10940: ADGRA3 in astrocytes, braak

power: full sample -0.01 (p 0.983, n 18), 95% CI -0.47 to +0.46. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.01 (p 0.969, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.11 (p 0.671, n 18). could be the mix.
skeptic: leave-one-out range -0.07 to +0.15, sign flips 4; without severely affected donors -0.01 (p 0.983, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ADGRA3 in astrocytes.

case closed: nothing better to follow up.

loading the receipts